These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12176465)

  • 1. Complete withdrawal of immunosuppression in living donor liver transplantation.
    Oike F; Yokoi A; Nishimura E; Ogura Y; Fujimoto Y; Kasahara M; Kaihara S; Kiuchi T; Egawa H; Uemoto S; Tanaka K
    Transplant Proc; 2002 Aug; 34(5):1521. PubMed ID: 12176465
    [No Abstract]   [Full Text] [Related]  

  • 2. Tacrolimus is effective in both dual and triple regimens after liver transplantation.
    Serrano J; García González M; Gómez M; Ortiz de Urbina J; López Cillero P; San Juan F; Parrilla P; Herrero JI
    Transplant Proc; 2002 Aug; 34(5):1529-30. PubMed ID: 12176469
    [No Abstract]   [Full Text] [Related]  

  • 3. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression.
    Ringe B; Braun F; Wietzke P; Oellerich M; Ramadori G
    Transplant Proc; 2000 Nov; 32(7):2543. PubMed ID: 11120285
    [No Abstract]   [Full Text] [Related]  

  • 4. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants.
    Sindhi R; Ganjoo J; McGhee W; Mazariegos G; Reyes J
    Transplant Proc; 2002 Aug; 34(5):1972-3. PubMed ID: 12176651
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
    Langrehr JM; Lohmann R; Raakow R; Jonas S; Klupp J; Bechstein WO; Neuhaus R; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
    [No Abstract]   [Full Text] [Related]  

  • 6. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation.
    Salizzoni M; Cavallari A; Risaliti A; Filipponi F; Gerunda GE; Forti D; Fassati LR; Cillo U; Castagneto M; Valente U; Tisone G
    Transplant Proc; 2001 May; 33(3):2258-62. PubMed ID: 11377521
    [No Abstract]   [Full Text] [Related]  

  • 7. Excellent 3-year results following living-donor kidney transplantation and tacrolimus immunosuppression in Japan.
    Uchida K; Takahashi K; Takahara S; Oshima S; Toma H; Sonoda T;
    Transplant Proc; 2002 Aug; 34(5):1606-7. PubMed ID: 12176503
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong.
    Lo CM; Fan ST; Liu CL; Chan KL; Ng IO; Lai CL; Lau GK; Fung SK; Wong J
    Transplant Proc; 1998 Nov; 30(7):3587-8. PubMed ID: 9838571
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.
    Lemmens HP; Langrehr JM; Blumhardt G; Lohmann R; Knoop M; Verschl J; Schattenfroh N; Neuhaus R; Hopf U; Bechstein WO
    Transplant Proc; 1994 Dec; 26(6):3622-3. PubMed ID: 7527983
    [No Abstract]   [Full Text] [Related]  

  • 10. Is the use of marginal liver grafts justified?
    Mueller AR; Platz KP; Krause P; Steinmüller T; Glanemann M; Neumann U; Lobeck H; Neuhaus P
    Transplant Proc; 1999; 31(1-2):401-2. PubMed ID: 10083160
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance.
    Takatsuki M; Uemoto S; Inomata Y; Sakamoto S; Hayashi M; Ueda M; Kanematsu T; Tanaka K
    Transpl Immunol; 2001 Feb; 8(4):279-86. PubMed ID: 11316071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK 506 rescue therapy: early conversion improves efficacy.
    Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.
    Klupp J; Glanemann M; Bechstein WO; Platz KP; Langrehr JM; Keck H; Settmacher U; Radtke C; Neuhaus R; Neuhaus P
    Transplant Proc; 1999; 31(1-2):1113-4. PubMed ID: 10083497
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospective evaluation of a quadruple therapy based on tacrolimus after liver transplantation.
    Lladó L; Figueras J; Ramos E; Lama C; Busquets J; Ibáñez L; Rafecas A; Fabregat J; Torras J; Jaurrieta E
    Transplant Proc; 2002 Feb; 34(1):108. PubMed ID: 11959210
    [No Abstract]   [Full Text] [Related]  

  • 15. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.
    Langrehr JM; Klupp J; Junge G; Jonas S; Neuhaus R; Bechstein WO; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2330-1. PubMed ID: 11377549
    [No Abstract]   [Full Text] [Related]  

  • 16. Weaning of immunosuppression in liver transplant recipients.
    Mazariegos GV; Reyes J; Marino IR; Demetris AJ; Flynn B; Irish W; McMichael J; Fung JJ; Starzl TE
    Transplantation; 1997 Jan; 63(2):243-9. PubMed ID: 9020325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
    Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
    [No Abstract]   [Full Text] [Related]  

  • 18. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids.
    Asensio M; Margarit C; Chavez R; Ortega J; Charco R; Iglesias J
    Transplant Proc; 2002 Aug; 34(5):1970-1. PubMed ID: 12176650
    [No Abstract]   [Full Text] [Related]  

  • 19. Living-related versus living-unrelated kidney transplantation using tacrolimus initial immunosuppression.
    Braun F; Canelo R; Lorf T; Schütz E; Grupp C; Müller GA; Ringe B
    Transplant Proc; 2000 Feb; 32(1):115-6. PubMed ID: 10700989
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
    Klupp J; Bechstein WO; Pratschke J; Tullius SG; Gebhard A; Lobeck H; Langrehr JM; Neuhaus R; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.